EF-1α-driven nanobody-based CD19-redirected CAR-T cells retain the antitumor efficacy, antigen-driven expansion, and cytokine secretion of CMV-driven counterparts

Copy APA Copied ✓ Copy MLA Copied ✓ Copy BibTeX Copied ✓